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The application of microfluidics to the synthesis of Positron Emission Tomography (PET) tracers has been
explored for more than a decade. Microfluidic benefits such as superior temperature control have been
successfully applied to PET tracer synthesis. However, the design of a compact microfluidic platform
capable of executing a complete PET tracer synthesis workflow while maintaining prospects for
commercialization remains a significant challenge. This study uses an integral system design approach to
tackle commercialization challenges such as the material to process compatibility with a path towards
cost effective lab-on-chip mass manufacturing from the start. It integrates all functional elements
required for a simple PET tracer synthesis into one compact radiochemistry platform. For the lab-on-chip
this includes the integration of on-chip valves, on-chip solid phase extraction (SPE), on-chip reactors and
a reversible fluid interface while maintaining compatibility with all process chemicals, temperatures and
chip mass manufacturing techniques. For the radiochemistry device it includes an automated chip-
machine interface enabling one-move connection of all valve actuators and fluid connectors. A vial-based
reagent supply as well as methods to transfer reagents efficiently from the vials to the chip has been
integrated. After validation of all those functional elements, the microfluidic platform was exemplarily
employed for the automated synthesis of a Gastrin-releasing peptide receptor (GRP-R) binding the
PEGylated Bombesin BN(7–14)-derivative ([18F]PESIN) based PET tracer.Introduction
Positron Emission Tomography (PET), a “molecular imaging”
technology, is a medical imaging technique that utilizes
radioactively labelled molecules (PET tracers) that are tailored
to interact with biological processes in vivo.1 After injection into
the patient, a PET tracer shall accumulate at areas of interest
according to its pharmacokinetic properties. Subsequently,the resulting radioactivity distribution in the patient is mea-
sured utilizing a PET scanner, today commonly in combination
with anatomic image acquisition from computer tomography
(PET/CT) or magnetic resonance imaging (PET/MR).
Regardless of the imaging device utilized, the majority of
the resulting diagnostic information is determined by the
biological or biochemical function of the PET tracer, indicat-
ing for example areas of increased or decreased sugar metab-
olism ([18F]Fludeoxyglucose), high cell membrane production
(e.g. [18F]Cholin) or receptor specific binding (e.g. [18F]Fallypride
for dopamine D2/D3 receptors). Therefore, new PET tracers
are currently under development by academic and industrial
entities. A major challenge associated with the transfer of
this increasing variety of radioactively labelled molecules into
clinical practice is the infrastructural burden associated with
the synthesis of PET tracers. Today, this step is performed by
automated synthesis devices (“synthesizers”) utilizing conven-
tional valves, tubing and glass vessels inside a lead shielded
work space (“hot cells”). One hot cell can result in a weight
of 8 tons while requiring a class C clean room environment
of approx. 1000 litres according to regulatory requirements.
This leads to significant costs and infrastructural constraints
for PET site erection, modification and routine PET traceroyal Society of Chemistry 2014
















View Article Onlineproduction. Furthermore, state of the art synthesizers utilize
reagent volumes from several hundred microliters to a few
millilitres for reasons of practicality. These volumes are sev-
eral orders of magnitude above the theoretically required
amount, since PET tracers are functional in nanomolar quan-
tities of the radioactively labelled molecules.
Intuitively, microfluidic technology was introduced to the
field, targeting a down-scaling of synthesizers to achieve a
reduced shielding size and weight as well as more efficient
chemical processing.2–13 For about one decade, numerous
microfluidic PET tracer synthesis setups have been described
including commercially available capillary-based microfluidic
synthesis platforms,14–16 as well as lab-on-chip devices.17–22
Significant improvements to PET tracer synthesis were dem-
onstrated such as reduced reaction times due to fast heat
transfer and high surface to volume ratios in microfluidics,
low consumption of potentially expensive reagents, fast opti-
mization of reaction conditions and low volume processing
of radioactivity levels sufficient for practical use.23–48
However, the large characteristic dimensions (including
all hardware periphery) of the microfluidic setups presented
as well as the system complexity exposed to the operator have
remained two major obstacles towards routine use. Further-
more, PDMS-based chip designs that capitalize on highly
integrated valves have been questioned due to the incompati-
bility of PDMS to fluoride-18 based radiochemistry.49
This study tackles those challenges and presents a radio-
chemistry system that unites all technical elements required
for a simple PET tracer synthesis in one compact, easy to use
device. First and foremost this includes a chip material with
full compatibility to process reagents and temperatures.
Second, the utilization of this material is enabled by a chip
manufacturing technology with potential for economy of
scale. Third, functional elements required for the execution
of the synthesis workflow are implemented into the chosen
chip material technology. These functional elements are
on-chip microfluidic reactors, on-chip fluid and gas control
by means of on-chip valves and associated compact off-chip
valve actuators, on-chip solid phase exchange (SPE) and a
connector interface between the chip and the hardware
periphery. To improve ease of use, the chip to hardware inter-
face is designed for full automation, enabling seamless chip
loading and unloading in a single motion. Reagents are
transferred from low dead-volume vials across the interface
by means of gas pressure driven fluid transport. All described
elements are integrated into a hardware assembly that has
potential for compact shielding architectures. The functional-
ity of the platform is exemplarily demonstrated by the com-




The ultimate target of synthesizing a PET tracer on a micro-
fluidic system in a routine environment is to provide a PETThis journal is © The Royal Society of Chemistry 2014image to a medical doctor at an acceptable cost.50 In this
context, the most important key figure is “cost per (PET)
dose”, which rolls up all elements of PET facility installation
and operation. Accordingly, cost is critical for the micro-
fluidic synthesizer as a system (e.g. reduced installation cost
by means of reduced shielding installation) as well as its
operation (e.g. cost of consumables).
Currently there are two fundamental microfluidic system
architectures in radiochemistry: chip-based and capillary-
based synthesizers. The advantage of chip-based microfluidic
devices is seen in the capability for cross-contamination-free
production of various PET tracers in series with no need for
manual hardware re-configuration or cleaning between runs
and therefore full compliance with regulatory requirements.
In this case, the microfluidic chip is replaceable, single-use
consumable and comparable to current synthesizers that are
utilizing disposable fluid path manifolds (“cassettes”) and a
set of reagents (“reagent kits”) that may be produced in sepa-
rate or as combined cassettes with integrated reagents (e.g.
GE FASTlab, GE Healthcare, Liege, Belgium). Today, one cas-
sette and one reagent kit are often used for the synthesis of
PET tracer “batches” that serve several patients at once, lead-
ing to a reduced contribution of consumables cost to the cost
per PET tracer dose.
In contrast, the major application of microfluidic PET
tracer synthesizers is seen in the area of small patient groups
(<10) that either require PET tracers “on demand” or are
located at hospitals with limited connectivity to PET tracer
distribution networks, also referred to as “de-centralized”
production sites.7 Hence, the manufacturing cost target for a
single microfluidic consumable including reagents has to be
expected at a fraction of today's consumables cost. Based on
the number of existing PET facilities worldwide and the lim-
ited growth of reimbursement for PET, the number of chips
required globally per year is estimated to be a few hundred
thousand. Both the high cost pressure on consumables and
the number of parts per year put significant limitations on
the materials and manufacturing methods that can be
employed to realize a lab-on-chip consumable that is com-
mercially viable.Microfluidic chip manufacturing
According to the cost constraints described, a materials study
was conducted and published in previous work.49 From this
study, injection mouldable cyclic olefin co-polymers (COCs)
were selected. Injection moulding and embossing are cost
effective methods for manufacturing of microfluidic parts
down to sub-micron geometric accuracy at a low production
cycle time per part.51,52 COC is compatible with many
reagents utilized in radiochemistry including strong acids
(e.g. hydrochloric acid), bases (e.g. sodium hydroxide), polar
organic solvents (e.g. dimethyl sulfoxide, acetonitrile or
dimethylformamide) and alcohols (e.g. ethanol). Beyond the
room temperature Silicon Fluoride Acceptor (SiFA) based
radiochemistry employed in this study, COC is compatibleLab Chip, 2014, 14, 2556–2564 | 2557
















View Article Onlinewith process temperatures of up to 150 °C such as for the
synthesis of the PET tracer, [18F]fluorothymidine ([18F]FLT).53
COC is further marked by its low raw material cost of around
one cent (US) per gram.49
COC 6017-S04 (TOPAS® Advanced Polymers GmbH,
Germany) was utilized for injection moulding of rectangular
blanks (Rodinger Kunststoff-Technik GmbH, Germany) with
outer dimensions of 100 mm × 100 mm × 2 mm. A COC
6015 film (TOPAS® Advanced Polymers GmbH, Germany) of
100 μm thickness was obtained to construct on-chip valves.
One microfluidic chip (Fig. 1) consists of three separate
layers (outer dimensions: each 95 mm × 60 mm × 2 mm), all
processed from the moulded blanks. All microfluidic struc-
tures on each of the layers are created utilizing a four axis
computerized numerical controlled (CNC) milling machine
(MDX-540 SA, Roland DGA Corp., USA). During microfluidic
chip design, compatibility with injection moulding tech-
niques was assured for all structures on-chip (RKT Rodinger
Kunststoff-Technik GmbH, Germany). After milling, all layers
including the foil were cleaned and assembled together with
the elements for on-chip valve and on-chip resin integration.
The assembly process was designed with potential for cost
effective pick-and-place automation. After assembly, all chip
elements were joined in a single thermal bonding step. No
additional cleaning, surface treatment, adhesives, ultrasound
nor laser processes were required.
On-chip valve
Due to the need for organic solvent compatibility
(e.g. dimethyl formamide or dimethyl sulfoxide), common
microfluidic valve designs that rely on flexible membrane
materials such as PDMS or Viton® are not suitable.54–582558 | Lab Chip, 2014, 14, 2556–2564
Fig. 1 Schematic of microfluidic chip assembly including the membrane vaThe membrane valve developed in this study utilizes a
floating FEP disk (DuPont FEP, part no. #536-3996, RS Com-
ponents GmbH, Germany) encapsulated by the chip substrate
(COC 6017) and a 100 μm thick cover membrane (COC 6015).59
The valve inlet and outlet can be prototyped by utilizing high
precision milling techniques and are suitable for injection
moulding. Due to the materials (COC and FEP) utilized, the
valve is compatible to acids, bases and organic solvents as
well as temperatures of up to 150 °C. After assembly and
bonding, the valve is normally open (Fig. 1). For valve clo-
sure, a spring loaded solenoid driven external plunger is
pressed on the COC membrane, driving the FEP disk against
the valve seat. This design leads to two fundamental advan-
tages: (a) the contaminated fluid path remains encapsulated
within the chip and (b) all valve actuators can be connected
and disconnected with the chip in a single automated
motion. A total number of 16 independently controllable
valves have been integrated into one microfluidic chip.
The valve design was characterized under realistic condi-
tions of use in terms of maximum pressure capability and
repeatable performance for 50 opening and closing cycles.
The valve leakage rate was determined by a simplified test
applying gas pressure to the valve inlet and subsequent
observation of bubble formation at the valve outlet.On-chip resin
The synthesis of PET tracers often requires functional resins
for the initial transfer of radioactive fluoride-18 from aqueous
to aprotic reaction conditions and for intermediate as well as
final product purification. Several techniques have been
reported including manual filling of on-chip cavities,60 on-chipThis journal is © The Royal Society of Chemistry 2014
lve and the insert assembly.
















View Article Onlinetrapping of solution suspended beads19 as well as introduc-
tion, photo-initiated polymerization and functionalization of
reactive compounds for monolithic on-chip columns.61 Even
though there have been successful efforts to reduce the need
for SPE-based process steps by means of electrochemical
methods62–69 or continuous flow microfluidics,70 the chal-
lenge remains for product purification, resulting in custom
made microcolumns external to the microfluidic chip.17,18,71
Future on-chip alternatives may involve periodic microstruc-
tures such as pillar arrays72 as well as functional surfaces.
However, all methods described impose challenges on pro-
cess chemistry, repeatability, compatibility with established
synthesis routines, reagent volumes and throughput, manu-
facturing complexity and economy of scale.
The resin integration method proposed in this work uti-
lizes an insert element that is pre-filled with conventional
resins, separating the integration workflow into three steps:
a) resin transfer to a low-cost carrier element (insert body,
compare Fig. 1) by means of conventional filling techniques;
b) assembly of the insert element into a recess on chip; and
c) connection to the on-chip fluid path during chip bonding.
The insert bodies are of simple geometry and milled from
COC 6015 (TOPAS® Advanced Polymers GmbH, Germany),
enabling compatibility with all relevant process chemicals,
temperatures and low cost injection moulding. The silica-
based resin material is extracted from the respective standard
cartridges and manually transferred to the COC 6015 insert
bodies creating phase transfer inserts and purification
inserts. Prior to bonding, the pre-assembled inserts are man-
ually positioned into milled recesses between the three micro-
fluidic chip layers, wherein each insert is slightly smaller in
two (X and Y) and larger in one dimension (Z) than the
recess. After chip assembly, the COC 6015 insert is thermo-
formed into the recess during chip bonding. This approach
capitalizes on the different glass transition temperatures
between COC 6015 (HDT/B = 150 °C) and COC 6017 (HDT/B =
170 °C). The required thermo-forming pressure is provided by
the geometric mismatch between the insert and the on-chip
recess and has to be adjusted based on the insert size.
The on-chip cartridges can be varied in number, packaged
resin size and location on the chip during chip design. For
future high volume production, cartridge manufacturing can
be standardized and manual assembly steps may be replaced
by e.g. pick-and-place automation.Fig. 2 Detailed view of the chip manifold in the open position with
the chip not completely inserted. The conic I/O ports as well as the
valve plungers can be connected within a single move to the on-chip
valves and conic ports.Chip interface for liquids and gases
The micro- to macro interface is a known challenge for
microsystems and numerous microfluidic connectors that
have been described in the literature.73 However, most solu-
tions are not compatible with the chemicals employed in PET
chemistry or are challenging to connect in an automated
fashion due to a multi-component design involving O-rings,
screws or adhesives.
Conventional high performance liquid chromatography
(HPLC) fittings capitalize on the mechanical advantage of aThis journal is © The Royal Society of Chemistry 2014wedge. The same principle is applied to the design presented
in this study utilizing conventional conical ferrules (F-142N
ETFE ferrules, Techlab GmbH, Germany) which are com-
pressed into conic recesses on the chip.74 At an on-chip cone
opening angle of 42° (recess depth 1.5 mm) a compression
force of 20 N between the ferrule and chip was found
sufficient to achieve liquid sealing (2-propanol) up to a pres-
sure of 100 bar. In order to compensate for mechanical
misalignment during automated chip loading and cross
forces resulting from thermal expansion of the chip when
operated at elevated temperatures, a compensation mecha-
nism75 has been implemented (Fig. 2). By this design, sealing
is achieved for 16 fluid ports and multiple opening and clos-
ing cycles. Similar to the valve actuators, connectivity
between the chip and the hardware is achieved in a single
automated motion.Reagent supply and loading
The gold standard for reagent storage in radiochemistry is
septa capped glass vials since this method is compatible to
long term storage of solvents such as DMSO. Accordingly,
reagents at a volume range between 50 μl and 2 ml are pro-
vided to the platform from septa capped low dead-volume
vials (Certified CD™ Vial, part no. 29307-U, Supelco Analytical,
USA). Since conventional Luer adapters show dead volumes
>10 μl, the vials are interfaced by a custom built low dead
volume connector. Each vial is connected via the adapter to
the chip interface using a single PEEK capillary line. This line
is utilized for gas pressurization of the vial as well as subse-
quent pressure driven unloading of the reagent to the chip.
Only on-chip valves are utilized to switch between vial pres-
surization and reagent unloading, minimizing the number of
transfer lines and the associated interface complexity as well
as the risk of leakages.
On-chip reagents are driven by gas pressure, in case accu-
rate metering of flow rates is not required (e.g. application ofLab Chip, 2014, 14, 2556–2564 | 2559
















View Article Onlineaqueous activity to the QMA cartridge). For accurate metering
(e.g. precise mixing during HEPES buffer dilution), two or
more syringe pumps of the control box can be employed
utilizing e.g. acetonitrile as mediators between the reagents
to be controlled on-chip and the syringe pump.Fig. 4 The chip manifold in the closed position (side view).Compact control hardware
The control hardware can be separated into two sub-systems:
(1) the chip manifold and (2) the control device (Fig. 3).
This arrangement is chosen with potential for “split-box”
or “self-shielded” architectures which provide shielding only
to system elements in contact with radioactive reagents, in
this case the chip and the surrounding chip manifold.32 This
approach is superior to conventional hot cell designs in
terms of weight, space consumption, installation cost and
flexibility.
The chip manifold contains the fluid interface with 16
input/output (I/O) ports and the valve actuator assembly
(Fig. 4). After manual chip insertion, the valve actuator inter-
face automatically compresses the chip against the fluid
interface by means of a motor driven mechanism, enabling a
connection of all chip control elements with one move.
Heating blocks enabling on-chip process operation at temper-
atures of up to 150 °C were integrated into the setup but not
used in this study.
A mechanism for chip ejection after process completion
has been integrated in order to demonstrate the prospect of
automated disposal of contaminated chips into shielded
waste areas for seamless “back-to-back” operation of consecu-
tive synthesis runs at low radiation exposure to the operator.
The control device contains all control electronics
required for on-chip valve actuation, chip loading and
unloading and five syringe pumps (Cavro® XCalibur, Tecan
Group Ltd., Switzerland) equipped with one 3-port rotary
valve each as well as a sensor for on-chip pressure monitor-
ing. The characteristic dimensions of the chip manifold are
250 × 135 × 130 (mm) and of the control box are 270 × 370 ×
210 (mm) making the system easily portable to various test sites.2560 | Lab Chip, 2014, 14, 2556–2564
Fig. 3 The microfluidic chemistry platform including the chip manifold,
microfluidic chip, control device and laptop.A LabVIEW-based software is employed for system control
via a laptop connected to the control device. The control soft-
ware separates the synthesis workflow into process steps,
wherein within each process step all system parameters can
be controlled and monitored. For a PET tracer synthesis, a
sequence of process steps can be programmed, saved, loaded
and modified, enabling full design flexibility to the operator.
Sequences can be executed automatically or between user-
defined breakpoints with the option of process step or
sequence modifications “on the fly”.
Proof-of-concept for SiFA radiochemistry
The radiolabeling of a PET tracer according to the SiFA
method was chosen as the proof-of-concept example. The
SiFA approach allows for a highly efficient isotopic exchange
reaction that simplifies the synthesis workflow by enabling
cartridge-based drying of fluoride-18.76–80
Bombesin analogues are imaging probes for oncological
applications. They are ligands of the gastrin-releasing-peptide
receptor (GRP-R) which is overexpressed on several tumor
tissues such as prostate, breast, ovarian, lung, colon and
gastrinoma cancers and therefore a feasible target structure
for tumor visualization with PET.81–83 The Bombesin deriva-
tive PESIN was tagged with a SiFA moiety and radiolabeled
on the microfluidic platform according to the following steps:
(1) loading of all reagents including aqueous fluoride-18
activity from vials; (2) fluoride-18 phase transfer from aque-
ous to aprotic reaction conditions; (3) radiolabeling; (4) puri-
fication; and (5) ejection of the radiolabelled [18F]PESIN PET
tracer into a product vial.
Results
Microfluidic chip
Depending on microfluidic structure complexity, the total
milling time per chip layer including loading and unloading
of blanks varied between 20 min and 120 min. Without fur-
ther optimization, the thermal bonding time was adjusted to
45 min and yielded chips without delamination defects. InThis journal is © The Royal Society of Chemistry 2014
Fig. 5 Cross-section of a QMA resin for 18-fluoride drying integrated
on a COC 6017 microfluidic chip.
















View Article Onlinethis way, different chip designs can be explored rapidly dur-
ing chip development with high degrees of design flexibility
for interconnecting valves, resins, reactors and I/O ports
on-chip. For economy of scale, improvements can be achieved
by customized injection moulding and solvent assisted bonding
for rapid and cost effective chip manufacturing.
During and after handling of acetonitrile, DMF, DMSO or
ethanol on-chip, no change in material color, transparency,
material abrasion or swelling was observed. No significant
chemical interaction was found between the chip material
and the fluoride-18 radioactivity nor any other reagent or
intermediate product utilized during the radiosynthesis
described. Several test chips were operated at up to 140 °C
resulting in no structural defects. This is consistent with
results reported in previous studies for DMSO at 113 °C and
HCl (1 M) at 80 °C.84
On-chip valve
Valve test structure fatigue was measured at an average gas
pressure load of 5.8 bar (min. 4.1 bar, max. 6.2 bar, standard
deviation 0.6 bar, 44 samples, pressure ramp up time 320 s ±
30 s). Improvements in increased pressure capabilities can be
achieved by a further reduction of the valve diameter below
6 mm.
Valve cycle tests resulted in zero valve failure over 50
switching cycles (n = 37 valves from 8 different test chips
investigated), which is the maximum load estimated for a
single PET tracer synthesis run on a chip-based consumable.
No change or cycle dependent drift was detected for the clos-
ing force or the gas flow rate across the open valve. This sug-
gests that the valve functionality is not significantly affected
by wearing effects such as membrane damage or valve seat
deformation over 50 cycles.
During gas leakage measurements, no gas bubble forma-
tion could be detected over a 1.0 min measurement time,
suggesting a gas leakage rate <0.1 μl min−1 at 2 bar gas pres-
sure and 4 N closing force on the valve plunger.
On-chip resin
For the evaluation of on-chip resin performance, insert ele-
ments were packed with the anion exchange resin material
from conventional cartridges (Sep-Pak® Light QMA Carbonate,
part no. 186004540, Waters Corp.) and bonded into dedicated
test chips by the method described. Fig. 5 shows a cross-
section of an on-chip QMA resin. The boundaries between
each insert element and the chip substrate material after
bonding are partially optically transparent, suggesting a very
good bond in these areas. The mechanical coupling between
the insert and the substrate can be understood as a labyrinth
sealing with the liquid pressure barrier significantly above
the actual pressure drop across the regular fluid path
through the cartridge. For cartridge functionality demonstra-
tion, the first steps of the [18F]PESIN protocol were executed
including fluoride-18 trapping, drying and subsequent
release into a vial. For this process, the overall fluoride-18This journal is © The Royal Society of Chemistry 2014losses were measured to be <11% (n = 3, decay corrected to
start of experiment) and are comparable to conventional car-
tridge performance. However, an increased pressure drop
across the on-chip cartridge of 1 bar to 3 bar higher than the
conventional equivalent cartridge was measured. Since the
resin geometry was kept comparable (L: 12 mm, B: 5 mm,
H: 5 mm, bore diameter ø 4 mm, 46 mg resin), the results
suggest a deformation of the insert element and a subse-
quent compression of the resin during bonding. This effect
could be compensated by an appropriate tolerance design
between the insert size and the on-chip recess size prior to
bonding as outlined before.
Reagent loading
The transfer efficiency of aqueous fluoride-18 from the vial to
chip according to the described gas pressurization method
for starting volumes ranging from 100 μl to 500 μl at initial
activities between 386 MBq (10.4 mCi) to 720 MBq (19.5 mCi)
was measured at an average of 97.8% (max. 99.6%, min.
93.5%, standard deviation 1.6%, 17 samples), based on the
comparison of vial activity before and after fluoride-18 load-
ing to chip, decay corrected to the start of the experiment.
Being the easiest quantifiable reagent for reagent transfer
characterization, the aqueous 18-fluoride loading shows the
efficiency of the presented approach and suggests a good
transfer of the other vial supplied reagents utilized in the
process. In fact, no synthesis failures from a lack of e.g. pre-
cursor or oxalic acid in the process could be detected.
Chemistry results
The total process efficiency, which is described by the frac-
tion of fluoride-18 activity transferred from the starting vial
(start of synthesis, SOS) into the purified [18F]PESIN product,
yielded 33% (±3%) (n = 4, not decay corrected) at >99%
radiochemical purity (Agilent 1200 radio-HPLC, Agilent Tech-
nologies Inc., USA) with starting activities between 243 MBq
(6.6 mCi) and 394 MBq (10.6 mCi). This overall efficiency is
slightly below the manual equivalent process (approx. 40%Lab Chip, 2014, 14, 2556–2564 | 2561
















View Article Onlineoverall efficiency at >99% radiochemical purity, not decay
corrected). The total process time was optimized to 36 min.
Residual activity on-chip after synthesis completion without
optimization of on-chip structures nor use of wash protocols
was measured to be <14% across all runs (decay corrected to
SOS). The described results were accomplished for a chip
design with cartridges external to the chip, connected via
capillary tubing across the described connector interface.
In a separate proof-of-concept experiment, both cartridges
were transferred on-chip while maintaining the remaining
chip design identical to the previous experiment (Fig. 6). This
resulted in an overall process efficiency of 12% (not decay
corrected) at >99% radiochemical purity in the first run. This
is comparable to the early performance of the cartridge
off-chip setup prior to chemistry protocol optimization.
The discrepancy results from the previously described
on-chip resin compression during bonding which led to
incorrect timing for mixing of reagents on-chip. This can be
addressed by chemistry protocol optimization and improved
cartridge insert design, suggesting that performance compa-
rable to conventional processing is achievable.Platform hardware
During test and evaluation of the microfluidic chemistry plat-
form for the SiFA chemistry, chips have been successfully
loaded and unloaded into the automated hardware over more
than 100 cycles. Occasional leakage of the Tefzel Ferrules at
the I/O ports due to deformation of the ferrule could be
addressed by simple ferrule replacement. Even though the
chips are design as single use disposable, they were used
multiple times in case cartridges were off-chip. Gas pressure
test protocols have been employed to ensure system function-
ality prior to the start of a synthesis. The platform was easy
to move between fume hoods, hot cells and test sites in
Europe and the United States at an average setup time of
<30 min. after relocation. Radiochemistry users could be
trained to operate the system within approx. one week.2562 | Lab Chip, 2014, 14, 2556–2564
Fig. 6 The microfluidic chip for complete [18F]PESIN synthesis with
valves, reactors, QMA and SPE resins integrated on-chip.Conclusion
With the recent FDA approval of new radiotracers for diagnosis
of Alzheimer's disease such as Vizamyl™ (GE Healthcare, USA)
and Amyvid™ (Eli Lilly, USA), the development of compact
cyclotrons (ABT Molecular Imaging, Inc., Louisville, TN, USA85
and PETtrace 600 prototype, GE Healthcare, Uppsala, Sweden)
and integrated quality control systems for PET tracer produc-
tion (QC1, Münster, Germany), the area is more vibrant than
ever before.
Cost per PET tracer dose is the main driver towards PET
imaging for small and de-central hospitals worldwide. Hence,
the objective of this study is not to demonstrate microfluidic
effects that push radiochemistry reactions to the extreme,
which is another reason why microfluidics is of interest in
this field, but rather develop an overall system solution that
fundamentally enables cost saving microfluidic technologies
to the clinical routine. Entering the development based on
process compatible COC materials, the resulting chip main-
tains compatibility to large scale manufacturing by means of
injection moulding and integration of all functional elements
required for a simple PET tracer synthesis workflow. Prag-
matic but viable solutions have been presented for on-chip
valve and on-chip resin integration. Interfacing to “the
macroworld”, the microfluidic chip has been made accessible
by a hardware interface that enables a reliable and auto-
mated chip exchange. The fully automated synthesis of the
PET tracer [18F]PESIN has been successfully implemented as
a proof-of-concept study at yields close to the conventional
process. Due to its compactness, the microfluidic radio-
chemistry platform including all hardware components can
be easily relocated while providing a system architecture
which is fundamentally compatible to very compact “self-
shielded” designs. In its current state and with the prototype
manufacturing for chips established, the platform is ready
for field tests with academic partners around the globe in
order to implement new PET tracer synthesis routines.
Looking beyond applications in PET radiochemistry, the
presented microfluidic chemistry platform can be extended
to other areas in chemistry and biology that require chip con-
sumables with high temperature and aggressive chemistry
requirements.
Acknowledgements
The authors gratefully acknowledge the financial support
from the Leading-Edge Cluster m4 and the German Federal
Ministry of Education and Research. Special thanks to
Arnaud Sors, Johannes Hass, Qing (Phoenix) Ba, Eva Bartok,
Eric Simon, Jing Meng, Yue Wang and Andre Yaroshenko for
their individual contribution.
References
1 M. E. Phelps, Proc. Natl. Acad. Sci. U. S. A., 2000, 97,
9226–9233.This journal is © The Royal Society of Chemistry 2014
















View Article Online2 V. Arima, G. Pascali, O. Lade, H. Kretschmer, I. Bernsdorf,
V. Hammond, P. Watts, F. De Leonardis, M. Tarn, N. Pamme,
P. S. Dittrich, B. Z. Cvetkovic, N. Vasovic, R. Duane, A. Jaksic,
A. Zacheo, A. Zizzari, L. Marra, E. Perrone, P. Salvadori and
R. Rinaldi, Lab Chip, 2013, 13, 2328–2336.
3 H. Audrain, Angew. Chem., Int. Ed., 2007, 46, 1772–1775.
4 A. M. Elizarov, Lab Chip, 2009, 9, 1326–1333.
5 R. Fortt and A. Gee, Future Med. Chem., 2013, 5, 241–244.
6 J. M. Gillies, C. Prenant, G. N. Chimon, G. J. Smethurst,B. A. Dekker and J. Zweit, Appl. Radiat. Isot., 2006, 64,
333–336.
7 P. Y. Keng, M. Esterby and R. M. van Dam, Positron
Emission Tomography - Current Clinical and Research Aspects,
ed. C.-H. Hsieh, InTech, New York, USA, 1st edn, 2012,
pp. 153–182.
8 S. Y. Lu and V. W. Pike, in PET chemistry: The driving force
in molecular imaging, ed. P. A. Schubiger, L. Lehmann and
M. Friebe, Springer Verlag, Berlin, Germany, 2006, pp. 271–289.
9 E. Liow, A. O'Brien, S. Luthra, F. Brady and C. Steel,
J. Labelled Compd. Radiopharm., 2005, 48, 28.
10 P. W. Miller, A. J. deMello and A. D. Gee, Curr. Radiopharm.,
2010, 3, 254–262.
11 G. Pascali, P. Watts and P. A. Salvadori, Microfluidics in
radiopharmaceutical chemistry, Nucl. Med. Biol., 2013, 40(6),
776–787.
12 C. K.-F. Shen, Microfluidic-assisted Radiochemistry and PET
Probe Synthesis, MI Gateway, 2011, 5(4), 1–5.
13 M. W. Wang, W. Y. Lin, K. Liu, M. Masterman-Smith and
K. F. C. Shen, Mol. Imaging, 2010, 9, 175–191.
14 E. Briard, S. S. Zoghbi, F. G. Siméon, M. Imaizumi,
J. P. Gourley, H. U. Shetty, S. Lu, M. Fujita, R. B. Innis and
V. W. Pike, J. Med. Chem., 2009, 52, 688–699.
15 G. Pascali, G. Mazzone, G. Saccomanni, C. Manera and
P. A. Salvadori, Nucl. Med. Biol., 2010, 37, 547–555.
16 H. J. Wester, B. W. Schoultz, C. Hultsch and G. Henriksen,
Eur. J. Nucl. Med. Mol. Imaging, 2009, 36, 653–658.
17 P. Y. Keng, S. Chen, H. Ding, S. Sadeghi, G. J. Shah,
A. Dooraghi, M. E. Phelps, N. Satyamurthy, A. F. Chatziioannou,
C. J. Kim and R. M. van Dam, Proc. Natl. Acad. Sci. U. S. A.,
2012, 109, 690–695.
18 A. M. Elizarov, M. R. van Dam, S. S. Young, H. C. Kolb,
H. C. Padgett, D. Stout, J. Shu, J. Huang, A. Daridon and
J. R. Heath, J. Nucl. Med., 2010, 51, 282–287.
19 C. Lee, G. Sui, A. M. Elizarov, C. J. Shu, Y. Shin,
A. N. Dooley, J. Huang, A. Daridon, P. Wyatt, D. Stout,
H. C. Kolb, O. N. Witte, N. Satyamurthy, J. R. Heath,
M. E. Phelps, S. R. Quake and H. R. Tseng, Science,
2005, 310, 1793–1796.
20 K. Liu, E. J. Lepin, M. W. Wang, F. Guo, W. Y. Lin,
Y. C. Chen, S. J. Sirk, S. Olma, M. E. Phelps, X. Z. Zhao,
H. R. Tseng, M. R. van Dam, A. M. Wu and C. K. Shen,
Mol. Imaging, 2010, 10, 168–176.
21 P. W. Miller, J. Chem. Technol. Biotechnol., 2009, 84, 309–315.
22 S. Chen, M. R. Javed, H.-K. Kim, J. Lei, M. Lazari, G. J. Shah,R. M. van Dam, P.-Y. Keng and C.-J. Kim, Lab Chip, 2014, 14,
902–910.This journal is © The Royal Society of Chemistry 201423 R. Bejot, A. M. Elizarov and E. Ball, J. Labelled Compd.
Radiopharm., 2011, 54, 117–122.
24 V. R. Bouvet, M. Wuest, P. H. Tam, M. Wang and F. Wuest,
Bioorg. Med. Chem. Lett., 2012, 22, 2291–2295.
25 V. R. Bouvet, M. Wuest, L. I. Wiebe and F. Wuest, Nucl. Med.
Biol., 2011, 38, 235–245.
26 S. Chen, R. Javed, J. Lei, H. K. Kim, G. Flores, R. M. van Dam,
P. Y. Keng and C. J. Kim, Technical Digest of the Solid-State
Sensor and Actuator workshop, Hilton Head Island, SC,
June 3–7, 2012, pp. 189–192.
27 T. Collier, M. Akula and G. Kabalka, J. Nucl. Med., 2010,
51, 1462.
28 F. De Leonardis, G. Pascali, P. A. Salvadori, P. Watts and
N. Pamme, Microfluidic modules for [18F−] activation –
Towards an integrated modular lab on a chip for PET
radiotracer synthesis, Proc. MicroTAS, 2010, 1604–1606.
29 V. Gaja, V. Gomez-Vallejo, M. Cuadrado-Tejedor, J. I. Borrell
and J. Llop, J. Labelled Compd. Radiopharm., 2012, 55,
332–338.
30 J. M. Gillies, C. Prenant, G. N. Chimon, G. J. Smethurst,
W. Perrie, I. Hamblett, B. Dekker and J. Zweit, Appl. Radiat.
Isot., 2006, 64, 325–332.
31 S. Kealey, C. Plisson, T. L. Collier, N. J. Long,
S. M. Husbands, L. Martarello and A. D. Gee, Org. Biomol.
Chem., 2011, 9, 3313–3319.
32 A. Lebedev, R. Miraghaie, K. Kotta, C. E. Ball, J. Zhang,
M. S. Buchsbaum, H. C. Kolb and A. M. Elizarov, Lab Chip,
2013, 13, 136–145.
33 S. Y. Lu, P. Watts, F. T. Chin, J. Hong, J. L. Musachio,
E. Briard and V. W. Pike, Lab Chip, 2004, 4, 523–525.
34 S. Y. Lu, A. M. Giamis and V. W. Pike, Curr. Radiopharm.,
2009, 2, 49–55.
35 S. Y. Lu and V. W. Pike, J. Fluorine Chem., 2010, 131,
1032–1038.
36 P. W. Miller, H. Audrain, D. Bender, A. J. deMello, A. D. Gee,
N. J. Long and R. Vilar, Chem. – Eur. J., 2011, 17, 460–463.
37 G. Pascali, G. Nannavecchia, S. Pitzianti and P. A. Salvadori,
Nucl. Med. Biol., 2011, 38, 637–644.
38 C. Rensch, B. Waengler, A. Yaroshenko, V. Samper,
M. Baller, N. Heumesser, J. Ulin, S. Riese and G. Reischl,
Appl. Radiat. Isot., 2012, 70, 1691–1697.
39 S. V. Selivanova, L. Mu, J. Ungersboeck, T. Stellfeld,
S. M. Ametamey, R. Schibli and W. Wadsak, Org. Biomol.
Chem., 2012, 10, 3871–3874.
40 C. J. Steel, A. T. O'Brien, S. K. Luthra and F. Brady,
J. Labelled Compd. Radiopharm., 2007, 50, 308–311.
41 R. W. Simms, P. W. Causey, D. M. Weaver, C. Sundararajan,
K. A. Stephenson and J. F. Valliant, J. Labelled Compd.
Radiopharm., 2012, 55, 18–22.
42 J. Ungersboeck, S. Richter, L. Collier, M. Mitterhauser,
G. Karanikas, R. Lanzenberger, R. Dudczak and W. Wadsak,
Nucl. Med. Biol., 2012, 39, 1087–1092.
43 J. Ungersboeck, C. Philippe, L. K. Mien, D. Haeusler,
K. Shanab, R. Lanzenberger, H. Spreitzer, B. K. Keppler,
R. Dudczak, K. Kletter, M. Mitterhauser and W. Wadsak,
Nucl. Med. Biol., 2011, 38, 427–434.Lab Chip, 2014, 14, 2556–2564 | 2563
















View Article Online44 J. Ungersboeck, C. Philippe, D. Haeusler, M. Mitterhauser,
R. Lanzenberger, R. Dudczak and W. Wadsak, Appl. Radiat.
Isot., 2012, 70, 2615–2620.
45 S. Voccia, J. L. Morelle, J. Aerts, C. Lemaire, A. Luxen and
G. Phillipart, J. Labelled Compd. Radiopharm., 2009, 52, i–xliii.
46 T. D. Wheeler, D. X. Zeng, A. V. Desai, B. Onal, D. E. Reichert
and P. J. A. Kenis, Lab Chip, 2010, 10, 3387–3396.
47 D. L. Yokell, A. K. Leece, A. A. Lebedev, R. R. Miraghaie,
C. E. Ball, J. J. Zhang, H. C. Kolb, A. M. Elizarov and
U. U. Mahmood, Appl. Radiat. Isot., 2012, 70, 2313–2316.
48 D. Zeng, A. V. Desai, D. Ranganathan, T. D. Wheeler,
P. J. A. Kenis and D. E. Reichert, Nucl. Med. Biol., 2013, 40, 42–51.
49 C. Rensch, A. Jackson, S. Lindner, R. Salvamoser, V. Samper,
S. Riese, P. Bartenstein, C. Wängler and B. Wängler,
Molecules, 2013, 18, 7930–7956.
50 R. G. Zimmermann, Nucl. Med. Biol., 2013, 40, 155–156.
51 U. M. Attia, S. Marsona and J. R. Alcockb, Microfluid.Nanofluid., 2009, 7, 1–28.
52 J. Steigert, S. Haeberle, T. Brenner, C. Müller, C. P. Steinert,P. Koltay1, N. Gottschlich, H. Reinecke, J. Rühe, R. Zengerle
and J. Ducrée, J. Micromech. Microeng., 2007, 17, 333–341.
53 H.-J. Machulla, A. Blocher, M. Kuntzsch, M. Piert, R. Wei and
J. R. Grierson, J. Radioanal. Nucl. Chem., 2000, 243, 843–846.
54 M. A. Unger, H. P. Chou, T. Thorsen, A. Scherer and
S. R. Quake, Science, 2000, 288, 113–116.
55 C. F. Chen, J. Liu, C.-C. Chang and D. L. DeVoe, Lab Chip,
2009, 9, 3511–3516.
56 I. R. G. Ogilvie, V. J. Sieben, B. Cortese, M. C. Mowlem and
H. Morgan, Lab Chip, 2011, 11, 2455–2459.
57 M. Bu, I. R. Perch-Nielsen and Y. Sun, et al., in Digest of
Technical Papers: Transducers 2011, Beijing, China, 2011,
pp. 1244–1247.
58 K. W. Oh and C. H. Ahn, J. Micromech. Microeng., 2006, 16,
R13–R39.
59 V. D. Samper, C. Rensch, C. Boeld and M. Baller, Patent
application, WO2011082276/A1, 2011.
60 F. De Leonardis, G. Pascali, P. A. Salvadori, P. Watts and
N. Pamme, J. Chromatogr. A, 2011, 1218, 4714–4719.
61 R. Ismail, K.-J. Park, M. R. van Dam and P. Keng, J. Nucl.
Med., 2012, 53, 572.
62 K. Hamacher, T. Hirschfelder and H. H. Coenen, Appl.
Radiat. Isot., 2002, 56, 519–523.
63 K. Hamacher and H. H. Coenen, Appl. Radiat. Isot., 2006, 64,
989–994.
64 D. Alexoff, D. J. Schlyer and A. P. Wolf, Appl. Radiat. Isot.,
1989, 40, 1–6.
65 G. Reischl, W. Ehrlichmann and H.-J. Machulla, J. Radioanal.
Nucl. Chem., 2002, 254, 29–31.
66 R. Wong, R. Iwata, H. Saiki, S. Furumoto, Y. Ishikawa and
E. Ozeki, Appl. Radiat. Isot., 2012, 70, 193–199.2564 | Lab Chip, 2014, 14, 2556–256467 H. Saiki, R. Iwata, H. Nakanishi, R. Wong, Y. Ishikawa,
S. Furumoto, R. Yamahara, K. Sakamoto and E. Ozeki, Appl.
Radiat. Isot., 2010, 68, 1703–1708.
68 F. Saito, Y. Nagashima, A. Goto, M. Iwaki, N. Takahashi,
T. Oka, T. Inoue and T. Hyodo, Appl. Radiat. Isot., 2007, 65,
524–527.
69 S. Sadeghi, V. Liang, S. Cheung, S. Woo, C. Wu, J. Ly,
Y. Deng, M. Eddings and R. M. van Dam, Appl. Radiat. Isot.,
2013, 75C, 85–94.
70 B. Cvetkovic, O. Lade, L. Marra, V. Arima, R. Rinaldi and
P. S. Dittrich, RSC Adv., 2012, 29, 11117–11122.
71 M. R. Javed, S. Chen, H.-K. Kim, L. Wei, J. Czernin,
C.-J. Kim, R. M. van Dam and P. Y. Keng, J. Nucl. Med.,
2014, 55, 1–8.
72 J. Billen and G. Desmet, J. Chromatogr. A, 2007, 1168,
73–99.
73 C. K. Fredrickson and Z. H. Fan, Lab Chip, 2004, 4, 526–533.
74 M. K. Baller, V. D. Samper and C. Rensch, Patent application,WO2012/015856A1, 2012.
75 C. Boeld, V. D. Samper, C. Rensch and R. J. Salvamoser,Patent application, US2012/0024405, 2012.
76 C. Wängler, S. Niedermoser, J. Chin, K. Orchowski,E. Schirrmacher, K. Jurkschat, L. Iovkova-Berends, A. P. Kostikov,
R. Schirrmacher and B. Wängler, Nat. Protoc., 2012, 7,
1946–1955.
77 C. Wängler, A. Kostikov, J. Zhu, J. Chin, B. Wängler and
R. Schirrmacher, Appl. Sci., 2012, 2, 277–302.
78 C. Wängler, B. Waser, A. Alke, L. Iovkova, H. G. Buchholz,
S. Niedermoser, K. Jurkschat, C. Fottner, P. Bartenstein,
R. Schirrmacher, J. C. Reubi, H. J. Wester and B. Wängler,
Bioconjugate Chem., 2010, 21, 2289–2296.
79 R. Schirrmacher, G. Bradtmöller, E. Schirrmacher, O. Thews,
J. Tillmanns, T. Siessmeier, H. G. Buchholz, P. Bartenstein,
B. Wängler, C. M. Niemeyer and K. Jurkschat, Angew. Chem.,
Int. Ed., 2006, 45, 6047–6050.
80 E. Schirrmacher, B. Wängler, M. Cypryk, G. Bradtmöller,
M. Schäfer, M. Eisenhut, K. Jurkschat and R. Schirrmacher,
Bioconjugate Chem., 2007, 18, 2085–2089.
81 J. C. Reubi, S. Wenger, J. Schmuckli-Maurer, J.-C. Schaer and
M. Gugger, Clin. Cancer Res., 2002, 8, 1139–1146.
82 D. Cornelio, R. Roesler and G. Schwartsmann, Ann. Oncol.,
2007, 18, 1457–1466.
83 V. Ambrosini, M. Fani, S. Fanti, F. Forrer and H. R. Maecke,
J. Nucl. Med., 2011, 52, 42S–55S.
84 C. Rensch, B. Wängler, C. Boeld, M. Baller, V. Samper,
N. Heumesser, W. Ehrlichmann, S. Riese and G. Reischl,
J. Nucl. Med., 2011, 52, 288.
85 V. Awasthia, J. Watsonb, H. Galia, G. Matlocka,
A. McFarlandb, J. Baileyb and A. Anzellottib, Appl. Radiat.
Isot., 2014, 89, 167–175.This journal is © The Royal Society of Chemistry 2014
